Efek Secretome Sel Punca Mesenkimal Terhadap Ekspresi Interleukin 17 Dan Tumor Necrosis Factor Alpha

Evi Liliek Wulandari, Arief Nurudhin, Arifin Arifin, Zainal Arifin Adnan

Abstract

Pendahuluan
Systemic Lupus Erythematosus (SLE) adalah penyakit inflamasi autoimun kronis yang belum jelas penyebabnya dengan gambaran klinis yang luas serta tampilan perjalanan penyakit beragam. Sitokin tertentu seperti IL-17 dan TNFα sangat terkait dengan pathogenesis SLE. Sel punca mensekresikan sejumlah protein (secretome) termasuk growth factor, kemokin, sitokin, metabolit dan lipid bioaktif yang mengatur secara autokrin atau parakrin
sambil merekayasa interaksi dengan lingkungan mikro sekitarnya. Penelitian ini bertujuan mengetahui pengaruh secretome sel punca mesenkimal terhadap ekspresi Interleukin 17 (IL-17) dan Tumor Necrosis Factor Alpha (TNF-α) pada mencit model lupus.

Metode Penelitian

Penelitian ini merupakan penelitian eksperimental dengan metode post test only control group design dengan randomisasi, sampel 21 mencit Balb/c betina, dibagi menjadi kelompok kontrol (injeksi NaCl 0,9% 0,5ml intraperitoneal), pristan (injeksi pristane 0,5ml intraperitoneal) dan pristan+secretome (injeksi pristan 0,5ml + secretome 0,45 ml intraperitoneal). Dilakukan pemeriksaan ekspresi IL-17 dan TNF- α jaringan ginjal ketiga
kelompok. Analisa statistik menggunakan SPSS 22 for windows. Uji beda rerata antara kelompok menggunakan uji F Anova bila distribusi data normal dan bila signifikan akan dilanjutkan dengan LSD Post Hoc Test. P bermakna jika p<0,05.

Hasil Penelitian

Hasil penelitian menunjukkan bahwa didapatkan hasil yang bermakna antara kelompok kontrol, pristan dan pristan+secretome baik pada kadar IL-17 (kontrol 6,9±1,95 ; pristan 9,9±2,27; pristan+secretome 6,1±1,95;  =0,016), dan TNF-α (kontrol 6,9±1,95; pristan 11,7±3,40; pristan+secretome 7,9±2,03; p=0,005).

Kesimpulan
Penelitian ini menunjukkan bahwa pemberian secretome sel punca mesenkimal berpengaruh menurunkan ekspresi IL-17 dan TNF- α pada mencit model lupus.

Kata kunci : Secretome, Interleukin 17, Tumor Necrosis Factor Alpha, Lupus

Keywords

secretome, interleukin 17, tumor necrosis factor alpha, lupus

Full Text:

PDF

References

  1. Mocarzel LOC, Lanzieri PG, Montes RA, Gismondi RAOC, Mesquita CT. Systemic Lupus Erythematosus: Review of Cardiovascular Aspects. International Journal of Cardiovascular Science 2015;28(3): 251-261.
  2. Comte BH, Karampetsou MP, Tsokos GC. T cells as a therapeutic target in SLE. Journal Lupus 2015;24:351-363.
  3. Chen J, Wu M, Wang J, Li X. Immunoregulation of NKT Cells in Systemic Lupus Erythematosus. Journal of Immunology Research 2015;20673:1-8.
  4. Suarjana IN. Imunopatogenesis Lupus Eritematosus Sistemik. Dalam : Simadibrata M, Syam AF, Setiati S, Setyohadi B, Alwi I (edt). Buku Ajar Ilmu Penyakit Dalam Jilid III. Edisi VI. Interna Publishing FK UI, Jakarta. 2014 : 3331-3345.
  5. Bertsias G, Cervera R, Boumpas DT. Systemic Lupus Erythematosus: Pathogenesis, Clinical Manifestations, And Diagnosis. Dalam : Cervera R, Espinosa G, D’Cruz D (edt). Eular Textbook of Rheumatic Disease. 2012: 476-505.
  6. Tsokos GC. Mechanism of Disease Systemic Lupus Erythematosus. New England Journal of Medicine 2011; 365(22):2110-2121.
  7. Hahn BH. The Pathogenesis of SLE. Dalam: Wallace DJ, Hahn BH (EDT). Dubois' Lupus Erythematosus and Related Syndromes. Eighth Edition. Saunders: Philadelphia. 2013: 25-35.
  8. Yap DYH dan Lai KN. Cytokines and Their Roles in Pathogenesis of Systemic Lupus Erythematosus: From Basics to Recent Advances. Journal of Biomedicine and Biotechnology 2010:1-10.
  9. Perhimpunan Reumatologi Indonesia. Rekomendasi Perhimpunan Reumatologi Indonesia Untuk Diagnosis dan Pengelolaan Lupus Eritematosus Sistemik. Perhimpunan Reumatologi Indonesia. 2011.
  10. Pelicari KO, Postal M, Sinicato NA, Peres FA, Fernandes PT, Marini R, et al. Serum interleukin-17 levels are associated with nephritis in childhood-onset systemic lupus erythematosus. Clinics 2015;70(5):313-317.
  11. Vincent FB, Northcott M, Hoi A, Mackay F, Morand EF. Clinical associations of serum interleukin-17 in systemic lupus erythematosus clinical associations of serum interleukin-17 in systemic lupus erythematosus. Arthritis Research & Therapy 2013;15:R97.
  12. Zhu LJ, Yang X, Yu XQ. Anti-TNF-α Therapies in Systemic Lupus Erythematosus. Journal of Biomedicine and Biotechnology 2010:1-7.
  13. Hirankarn N, Avihingsanon Y, Wongpiyabovorn J. Genetic susceptibility to SLE is associated with TNF-alpha gene polymorphism –863, but not –308 and –238, in
    Thai population. International Journal of Immunogenetics 2007;34:425–430.
  14. Meirelles LDS, Fontes AM, Covas DT, Caplan AI. Mechanism Involved in the Therapeutic Properties of Mesenchymal Stem Cells. Cytokine Growth Factor Review 2009; 20: 419-427.
  15. Carrion FA, Figueroa FE. Mesenchymal Stem Cells for the Treatment of Systemic Lupus Erythematosus: Is the Cure for Connective Tissue Disease Within
    Connective Tissue?. Stem Cell Research & Therapy 2011;2(23):1-8.
  16. Wang Y, Bakota E, Chang BHJ, Entman M, Hartgerink JD, Danesh FR. Peptide Nanofibers Preconditioned with Stem Cell Secretome Are Renoprotective.
    Journal of The American Society Nephrology, 2011; 22: 704–717.
  17. Drago D, Cossetti C, Iraci N, Gaude E, Musco G, Bachi A, Pluchino S. The Stem Cell Secretome and It’s Role in Brain Repair. Biochimie, 2013;95: 2271-2285.
  18. Madrigal M, Rao KS, Riordan NH. A Review of Therapeutic Effects of Mesenchymal Stem Cell Secretions and Induction of Secretory Modification by Different Culture Methods. Journal of Translational Medicine, 2014;12(260):1-14.
  19. Musai M. Terapi Lupus Eritematosus Sistemik dengan Penghambatan Kostimulasi Sel T. Majalah Kedokteran Indonesia, 2010;60(10): 1-6.
  20. Rottman JB dan Willis CR. Mouse Models of Systemic Lupus Erythematosus Reveal a Complex Pathogenesis. Veterinary Pathology, 2010; 47(4): 664- 676.
  21. Reeves WH, Lee PY, Weinstein JS, Satoh M, Lu L. Induction of Autoimmunity by Pristane and Other Naturally Occurring Hydrocarbons. Trends in Immunology, 2009;30(9): 455–464.
  22. Calvani N, Caricchio R, Tucci M, Sobel E, Silvestris P, Tartaglia P, Richards HB. Induction of Apoptosis by the Hydrocarbon Oil Pristane: Implications for Pristane-Induced Lupus. The Journal of Immunology, 2007;2005(175): 4777-4782.
  23. Figueroa FE, Carrión F, Villanueva S, Khoury M. Mesenchymal Stem Cell treatment for autoimmune diseases: a critical review. Biological Research, 2012;2012(5):269-277.
  24. Sun L, Wang D, Liang J, Zhang H, Feng X, Wang H. Umbilical Cord Mesenchymal Stem Cell Transplantation in Severe and Refractory Systemic Lupus Erythematosus. Arthritis & Rheumatism, 2010;62(8): 2467-2475.
  25. Liang J, Zhang H, Hua B, Wang H, Lu L, Shi S, et al. Allogenic Mesenchymal Stem Cell Transplantation in Refractory Systemic Lupus Erythematosus: A Pilot Clinical Study. Annals of the Rheumatic Disease, 2010;2010(69): 1423-1429.
  26. Hoetzenecker K, Zimmermann M, Hoetzenecker W, Schweiger T, Kollmann D, Mildner M, et al. Mononuclear cell secretome protects from experimental autoimmune myocarditis. European Heart Journal, 2013;2013(10):1-11.
  27. Chang CP, Chio CC, Cheong CU, Chao CM, Cheng BC, Lin M. Hypoxic preconditioning enhances the therapeutic potential of the secretome from cultured human mesenchymal stem cells in experimental traumatic brain injury. Clinical Science, 2013;2013(124): 165–176.

DOI: https://doi.org/10.13057/smj.v5i1.48954

Refbacks

  • There are currently no refbacks.